Escalating Doses of Memantine in Down Syndrome (MEDS-123) | MicrobiomeTrials← Back to trialsNCT07531940
Escalating Doses of Memantine in Down Syndrome (MEDS-123)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2028-05
Enrollment target: 25 participants Locations- University Hospitals Case Medical Center, Cleveland, Ohio, United States
Other microbiome trials you might be interested in
Myelodysplastic Syndromes
Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorder…
Bethesda, United StatesEst. completion Jan 1, 2030
Down SyndromeChild Obesity
The goal of this project is to evaluate an adapted health promotion program, HomeGrown, designed to improve the health o…
Chapel Hill, United StatesEst. completion May 2027
Recruiting
Background:
Down syndrome is a genetic disorder that can cause heart defects and other problems in the body. People wit…
Bethesda, United StatesEst. completion May 1, 2040